Compare Vanguard High Dividend Yield ETF (VYM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard High Dividend Yield ETF trades at $158.75 (market cap $100.80B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 10× State Street SPDR S&P Biotech ETF's market cap, and Vanguard High Dividend Yield ETF is more actively traded (908,176 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard High Dividend Yield ETF for 139 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VYM | XBI | |
|---|---|---|
Market Cap | $100.80B | $10.11B |
Volume | 908,176 | 12,903,266 |
52-Week High | $167.03 | $169.55 |
52-Week Low | $137.47 | $104.99 |
Typical Hold Time | 139 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $158.75, up 0.83% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments, with a recent $0.89 dividend declared for September 2026. Technical indicators show mixed signals with neutral oscillators and key support at $156. Recent media coverage highlights VYM's role in income strategies but notes competitive pressure from alternative dividend ETFs offering higher yields and performance.
VYM faces headwinds from underperformance relative to peers like SCHD and IDV, with concerns about dividend sustainability in its holdings. The ETF's broad diversification provides stability but limits upside potential. Key risks include sector concentration in dividend-cut vulnerable stocks and competitive yield pressures. Analyst sentiment remains neutral given its steady but modest income profile.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
